Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Even though the stock has become cheaper, we don't have much confidence in Incyte. Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...